Combination treatments for myelofibrosis in JAK inhibitor‑naive patients: evidence, rationale, and clinical direction.
Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) characterized by splenomegaly, constitutional symptoms, cytopenias, bone marrow fibrosis.
This review focuses on combination therapies in patients with myelofibrosis (MF) who are naive to JAK inhibitors. We summarize the available clinical evidence from phase 2 and particularly 3 studies that evaluate combinations of JAK inhibitors with agents that target epigenetic regulation, apoptosis, inflammation, and fibrogenesis. Selected combination therapies show promise for improving the depth and durability of response compared with JAK inhibitor monotherapy.
The article discusses strategies to improve disease outcomes in untreated myelofibrosis patients, highlighting the potential benefit of combination treatments.
Evidence level: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Related signals
- ASH 2024: New Research, Data Drive Progress in Myelofibrosis
- Single agent selinexor is active in patients with myelofibrosis refractory or intolerant to JAK inhibitors
- Population Pharmacokinetics and Exposure‑Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis
- SOHO 2026: Imetelstat Efficacy in Myelofibrosis - GERN
- Current treatments, practical management, and emerging investigational therapies for myelofibrosis